Shares of AstraZeneca plc (ADR) (NYSE:AZN) ended Thursday session in green amid volatile trading. The shares closed up +0.13 points or 0.39% at $33.65 with 3.43 million shares getting traded. Post opening the session at $33.98, the shares hit an intraday low of $33.59 and an intraday high of $34.06 and the price vacillated in this range throughout the day. The company has a market cap of $83.07 billion and the numbers of outstanding shares have been calculated to be 1.26 billion shares.
AstraZeneca plc (ADR) (AZN) on July 18, 2016 announced that the AURA3 Phase III trial met its primary endpoint, demonstrating superior progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy. The AURA3 randomized trial assessed the efficacy and safety of TAGRISSO® (osimertinib) as a second-line treatment in more than 400 patients with EGFR T790M mutation-positive, locally-advanced or metastatic NSCLC, whose disease had progressed following first-line EGFR tyrosine kinase inhibitor (TKI) therapy. TAGRISSO also demonstrated a safety profile consistent with previous trials.
In addition to PFS, the objective response rate (ORR), disease control rate (DCR) and duration of response (DoR) also achieved clinically meaningful improvement versus chemotherapy. A full evaluation of AURA3 data, including an analysis of overall survival (OS), is ongoing, and results will be presented at an upcoming medical meeting.
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These results confirm TAGRISSO as a meaningful alternative to benefit EGFR T790M lung cancer patients. The AURA3 results demonstrate the benefits of our science-led approach that enabled the rapid development of TAGRISSO as a targeted treatment to address the most common cause of resistance to a first-generation EGFR-TKI for patients with metastatic EGFR-mutant lung cancer. We remain committed to exploring the potential of TAGRISSO to further extend its reach and help meet patient need.”
Shares of Johnson & Johnson (NYSE:JNJ) ended Thursday session in green amid volatile trading. The shares closed up +0.29 points or 0.25% at $117.95 with 5.19 million shares getting traded. Post opening the session at $118.17, the shares hit an intraday low of $117.69 and an intraday high of $118.24 and the price vacillated in this range throughout the day. The company has a market cap of $321.09 billion and the numbers of outstanding shares have been calculated to be 2.74 billion shares.
Johnson & Johnson (JNJ) on Sept. 20, 2016 announced a new five-year commitment to help advance the United Nations Sustainable Development Goals to help improve the health and well-being of men, women and children around the world. Johnson & Johnson is dedicating its expertise and innovations to ignite global partnerships and catalyze efforts through a variety of new implementation plans, targets and metrics. The announcement comes along with an expanded commitment by Johnson & Johnson to further strengthen the resilience of refugee and displaced children and their families in Syria and its neighboring countries where the need is greatest.
“Johnson & Johnson is committed to creating greater access to quality health care across the globe,” said Johnson & Johnson Chairman and CEO Alex Gorsky. “Beyond developing medicines, equipment and vaccines, we’re in communities helping expectant mothers take better care of themselves and their babies during pregnancy. We’re training nurses and doctors to identify and treat diseases, and also funding medical research. We’re proud to take a leading role with the world community in this effort, which will go a long way toward creating a healthier society.”